US to spend billions on more doses

Plan aims to boost availability, build world stockpile

WASHINGTON — Pressed to address gaping inequality in global COVID-19 vaccines, the Biden administration took steps Wednesday to make billions of dollars available to drugmakers to scale up domestic production to share with the world and prepare for the next pandemic.

Under the new initiative, the government’s Biomedical Advanced Research and Development Authority is soliciting pharmaceutical companies with proven ability to make the moreeffective mRNA vaccines to bid for U.S. investment in scaling up their manufacturing. Pfizer and Moderna produce the two U.S.approved mRNA shots.

The White House hopes the move will build capacity to produce an additional 1 billion shots per year.

The initiative comes as the Biden White House has faced growing pressure at home and abroad over inequity in the global vaccine supply — as the U.S. moves toward approving booster shots for all adults while vulnerable people in poorer nations wait for their first dose of protection.

According to an analysis by the ONE Campaign, an international aid and advocacy organization, only 4.7% of people living in low-income countries have received a first dose. Wealthy nations administered more than 173 million booster shots, while lower-income countries have administered about 32 million first shots.

The Biden administration believes increasing capacity of COVID-19 shots will help ease a global shortage of doses, particularly in lowerand middle-income nations, stopping preventable death and limiting the development of potentially new, more dangerous variants of the virus. “The goal of this program is to expand existing capacity by an additional billion doses per year, with production starting by the second half of 2022,” White House COVID-19 coordinator Jeff Zients said.

On Wednesday, Zients announced that the U.S. has now donated 250 million doses of COVID-19 vaccines globally — the most of any nation — with a goal of sharing more than 1.1 billion shots by the end of 2022.

There are no firm agreements yet with Moderna or Pfizer to take up the U.S. on the investment, but the Biden administration hopes that the enhanced manufacturing capacity, through support for the company’s facilities, equipment, staff or training, will by mid-2022 allow more COVID-19 doses to be shared overseas as well as help prepare for the next public health emergency.